Brief: Hookipa Announces First Patient Enrolled In Phase 2 Trial Evaluating Hb-200 And Pembrolizumab For Treatment Of Head And Neck Cancer And Reports FDA’S Fast Track Designation

So-Young International

18/01/2022 13:57

Jan 18 (Reuters) - HOOKIPA Pharma Inc  HOOK.O :
    * HOOKIPA ANNOUNCES FIRST PATIENT ENROLLED IN PHASE 2 TRIAL
EVALUATING HB-200 AND PEMBROLIZUMAB FOR TREATMENT OF HEAD AND
NECK CANCER AND REPORTS FDA’S FAST TRACK DESIGNATION

Source text for Eikon:  ID:nGNX4G6qxS 
Further company coverage:  HOOK.O